Neogen's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Neogen's ROA in the fourth quarter of 2026?
Neogen Corporation recorded a cumulative net loss of $-8 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -0.23%.

However, within the Healthcare sector 215 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the May 31 2026 quarter, so far to 3415, from total ROA ranking in the third quarter of 2026 at 3974.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(May 31 2026) IV. Quarter	(Feb 28 2026) III. Quarter	(Nov 30 2025) II. Quarter	(Aug 31 2025) I. Quarter	(May 31 2025) IV. Quarter
Y / Y Total Assets Change	2.91 %	-16.47 %	-24.4 %	-25.11 %	-24.36 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-8	-609	-603	-1,043	-1,092
Return On Assets (TTM)	-0.23 %	-17.93 %	-16.92 %	-27.18 %	-26.5 %
NEOG's Total Ranking	# 3415	# 3974	# 3701	# 3715	# 3330
Total Assets (TTM) in million	3,531	3,359	3,429	3,364	3,431
Seq. Total Assets Change	5.12 %	-2.05 %	1.94 %	-1.96 %	-14.68 %
Seq. Net Income Change	-	-	-	-	-

NEOG's 5 Years Annual ROA >> Back to NEOG Management Effectiveness >> Compare NEOG ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 2
Sector	# 216
Overall	# 2566

Return On Assets Statistics
High	Average	Low
11.17 %	4.03 %	-27.08 %
(Aug 31 2018)		(Aug 31 2025)

Financial Statements
Neogen's Assets	$ 3,531 million	NEOG's Balance sheet
Neogen's Income	$ -11 million	Quarterly NEOG's Income Statement
NEOG's Income by Division		See NEOG's Income by Division

Annual Return On Assets	(May 31 2026) FY 2026	(May 31 2025) FY 2025	(May 31 2024) FY 2024	(May 31 2023) FY 2023	(May 31 2022) FY 2022
Y / Y Total Assets Change	2.97 %	-24.4 %	-0.22 %	358.43 %	7.77 %
Total Assets in million	3,531	3,429	4,536	4,546	992
Y / Y Net Income Change	-	-	-	-	-20.65 %
Net Income in million	-8	-1,092	-9	-23	48
Annual Return On Assets	-0.22 %	-31.84 %	-0.21 %	-0.5 %	4.87 %

NEOG's 5 Years Annual ROA >> Back to NEOG Management Effectiveness >> Compare NEOG ROA to its Competitors

More Return On Assets Ratios
NEOG's' Return on Assets at Yahoo Finance
In Vitro & In Vivo Diagnostic Substances Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NEOG's Roa Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NEOG's Competitors
Subscribers only: Roa for Neogen's Suppliers
Subscribers only: Return On Assets for NEOG's Customers

You may also want to know
NEOG's Roi	NEOG's Inventory Turnover Ratio	NEOG's Growth Rates	NEOG's Dividend Comparisons
	NEOG's Profitability Ratios	NEOG's Asset Turnover Ratio	NEOG's Dividend Growth
NEOG's Roe	NEOG's Valuation Ratios	NEOG's Financial Strength Ratios	NEOG's Dividend Payout Ratio

Companies with similar Return On Assets at May 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T09:58:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.